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Background
The attenuated poxvirus vectors MVA and NYVAC are now
in clinical trials against HIV/AIDS. Due to the vectors
restricted replication capacity in human cells, approaches
to enhance their immunogenicity are highly desirable.
Methods
Here, we have analyzed the ability of a soluble form of
hexameric CD40L (sCD40L) to stimulate specific
immune responses to HIV antigens when inoculated in
mice during priming with DNA and in the booster with
MVA or NYVAC, expressing the vectors HIV-1 Env, Gag,
Pol and Nef antigens from clade B.
Results
Our findings revealed that sCD40L in DNA/poxvirus com-
bination enhanced the magnitude about 2-fold (DNA-B/
MVA-B) and 4-fold (DNA-B/NYVAC-B), as well as the
breath of the HIV antigen specific cellular immune
responses. sCD40L was necessary in both prime and boost
inoculations triggering a potent polarization of the the
response towards a Th1 type. In DNA-B/NYVAC-B regime
the addition of sCD40L significantly enhanced the
humoral immune response against HIV gp160, but not in
DNA-B/MVA-B combination.
Conclusion
These findings provided evidence for the immunostimu-
latory benefit od sCD40L when DNA and the poxvirus
vectors MVA and NYVAC are used as immunogens.
from AIDS Vaccine 2009
Paris, France. 19–22 October 2009
Published: 22 October 2009
Retrovirology 2009, 6(Suppl 3):P9 doi:10.1186/1742-4690-6-S3-P9
<supplement> <title> <p>AIDS Vaccine 2009</p> </title> <editor>Anna Laura Ross</editor> <note>Meeting abstracts – A single PDF containing all abstracts in this Supplement is available <a href="http://www.biomedcentral.com/content/files/pdf/1742-4690-6-S3-full.pdf">here</a>.</note> <url>http://www.biomedcentral.com/content/pdf/1471-2105-10-S12-info.pdf</url> </supplement>
This abstract is available from: http://www.retrovirology.com/content/6/S3/P9
© 2009 Najera et al; licensee BioMed Central Ltd. 
